Last reviewed · How we verify
CAM2029
CAM2029 is a long-acting buprenorphine formulation designed to provide sustained opioid receptor agonism for opioid use disorder treatment.
CAM2029 is a long-acting buprenorphine formulation designed to provide sustained opioid receptor agonism for opioid use disorder treatment. Used for Opioid use disorder (maintenance treatment).
At a glance
| Generic name | CAM2029 |
|---|---|
| Also known as | octreotide subcutaneous depot |
| Sponsor | Camurus AB |
| Drug class | Opioid receptor partial agonist (long-acting formulation) |
| Target | Mu-opioid receptor (partial agonist) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Addiction Medicine |
| Phase | Phase 3 |
Mechanism of action
CAM2029 is a subcutaneous depot injection of buprenorphine that delivers the drug over an extended period, reducing the need for frequent dosing. Buprenorphine is a partial mu-opioid receptor agonist that reduces cravings and withdrawal symptoms in opioid-dependent patients while carrying lower overdose risk than full agonists. The extended-release formulation aims to improve treatment adherence and reduce illicit opioid use.
Approved indications
- Opioid use disorder (maintenance treatment)
Common side effects
- Injection site reactions
- Headache
- Constipation
- Nausea
- Hyperhidrosis
Key clinical trials
- A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (PHASE3)
- A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD (PHASE2, PHASE3)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (PHASE3)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (PHASE3)
- Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAM2029 CI brief — competitive landscape report
- CAM2029 updates RSS · CI watch RSS
- Camurus AB portfolio CI